Mortality on DOACs Versus on Vitamin K Antagonists in Atrial Fibrillation: Analysis of the Hungarian Health Insurance Fund Database.

MLA

Papp, Tímea, et al. “Mortality on DOACs Versus on Vitamin K Antagonists in Atrial Fibrillation: Analysis of the Hungarian Health Insurance Fund Database.” Clinical Therapeutics, vol. 45, no. 4, Apr. 2023, pp. 333–46. EBSCOhost, https://doi.org/10.1016/j.clinthera.2023.03.008.

APA

Papp, T., Kiss, Z., Rokszin, G., Fábián, I., Márk, L., Bagoly, Z., Becker, D., Merkely, B., Aradi, D., Dézsi, C. A., Járai, Z., & Csanádi, Z. (2023). Mortality on DOACs Versus on Vitamin K Antagonists in Atrial Fibrillation: Analysis of the Hungarian Health Insurance Fund Database. Clinical Therapeutics, 45(4), 333–346. https://doi.org/10.1016/j.clinthera.2023.03.008

Chicago

Papp, Tímea, Zoltán Kiss, György Rokszin, Ibolya Fábián, László Márk, Zsuzsa Bagoly, Dávid Becker, et al. 2023. “Mortality on DOACs Versus on Vitamin K Antagonists in Atrial Fibrillation: Analysis of the Hungarian Health Insurance Fund Database.” Clinical Therapeutics 45 (4): 333–46. doi:10.1016/j.clinthera.2023.03.008.